The short version of protease fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
Hydrolysates usually contain 70% to 90% protein on a dry basis, with variable ash, fat, and carbohydrate. Solubility in water is generally high over a broad pH range, though bitter notes can appear from exposed hydrophobic peptides. The powder tends to absorb moisture and may brown during prolonged warm storage. Applications span sports nutrition, clinical nutrition, infant formulas, and flavor systems. Regulatory status and labeling rules differ by country. A key open question is whether a given peptide profile reliably predicts functional or sensory behavior across different food matrices.
Whey protein hydrolysate is a dairy ingredient made by breaking peptide bonds in whey proteins. Enzymes such as proteases, or in some processes acid or heat, cleave the protein chains into shorter peptides and free amino acids. The starting material may be sweet whey, acid whey, whey protein concentrate, or whey protein isolate. Because raw materials and reaction conditions differ, the final mixture is not a single uniform substance. Its peptide profile, mineral content, and residual lactose depend on the source and the processing steps used.
Commercial production usually begins with whey protein concentrate or isolate, not raw whey, to reduce fat and lactose. Food-grade proteases from bacterial or plant sources are added under controlled temperature and pH, then inactivated by heat or pH adjustment. The resulting liquid may be clarified, filtered, concentrated, and spray-dried into powder. Enzyme choice, reaction time, and pretreatment conditions create products with different peptide size distributions. Because these variables are proprietary and not standardized, two hydrolysates with the same degree of hydrolysis can differ in peptide sequences and mineral content.
Composition reflects both the original whey and the hydrolysis process. Products contain protein-derived peptides, variable ash, moisture, and residual lactose or fat depending on filtration. Some free amino acids increase during hydrolysis, and bitterness often rises with higher degrees of hydrolysis due to exposed hydrophobic residues. Mineral profiles vary with the whey source and any neutralization step. Allergenicity may be reduced in extensively hydrolyzed products, but the extent depends on residual intact protein and peptide size, and this remains a subject of ongoing study.
Whey protein hydrolysate is a dairy-derived ingredient made by treating whey protein with enzymes or acid to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese manufacture, which contains beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin, and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and taste. The extent of breakdown is described by degree of hydrolysis, a percentage of cleaved peptide bonds. This value influences functional and sensory properties but does not by itself define a specific molecular profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow powder | Color varies with whey source and drying. |
| Protein content | 75–90% of dry matter | Depends on raw material and filtration. |
| Hydrolysis extent | 5–35% cleaved bonds | Ranges overlap product types; assay-dependent. |
| Water solubility | High across pH 3–7 | Hydrolysis raises solubility versus intact protein. |
| Typical storage | 15–25 °C, dry | Keep sealed; limit moisture and heat. |
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
Whey protein hydrolysate is a dairy ingredient produced by treating whey protein concentrate or isolate with proteolytic enzymes, acids, or heat under controlled conditions. The process cleaves peptide bonds and reduces average peptide size compared with intact whey proteins. Products are often described by degree of hydrolysis, which estimates the percentage of peptide bonds broken. Hydrolysates occupy a distinct category from concentrates and isolates because their peptide profile, solubility, and taste differ, even when the parent protein source is similar. Commercial production typically begins with pasteurized whey, followed by filtration, enzymatic treatment, inactivation, and drying.
Production usually starts with whey protein concentrate or isolate. The material is dissolved, pasteurized, and adjusted to conditions that favor a chosen protease, such as trypsin, pepsin, or papain. Enzyme choice, pH, temperature, and reaction time determine peptide length, terminal residues, and functional behavior. After hydrolysis, the enzyme is inactivated by heat or pH change, and the liquid is clarified, filtered, concentrated, and dried. Membrane filtration can further fractionate peptides and remove some minerals or lactose. The final powder is typically spray-dried.
Composition reflects the whey source and the extent of hydrolysis. Beta-lactoglobulin and alpha-lactalbumin fragments are common, and sweet whey may contribute glycomacropeptide. The amino acid profile remains broadly similar to intact whey protein, but peptide size affects how quickly nitrogen appears in blood after ingestion. Bitter notes often arise from short peptides with hydrophobic residues. Hydrolysates are used in sports nutrition, infant formula, and clinical nutrition, though effects on muscle, immunity, or allergy risk are separate research questions rather than guaranteed properties.
Whey protein hydrolysate is made by cleaving peptide bonds in whey proteins. The starting material is usually whey protein concentrate or isolate obtained during cheese or casein production. Proteolytic enzymes, acid, or heat can drive hydrolysis, although commercial processes favor controlled enzymatic treatment. The degree of hydrolysis describes the proportion of peptide bonds broken and separates partial from extensive hydrolysates. The resulting powder contains short peptides, free amino acids, residual intact protein, minerals, lactose, and fat in proportions that depend on the starting whey and downstream filtration.
Molecular weight distribution is a central compositional feature, and hydrolysis shifts the population toward lower-mass peptides, often below ten kilodaltons in extensively treated products. Enzyme choice, reaction time, temperature, pH, and enzyme-to-substrate ratio influence the peptide profile. Ultrafiltration or diafiltration may remove enzymes, salts, and smaller molecules. Because peptide size affects solubility, taste, foaming, and digestibility, manufacturers specify molecular weight ranges. However, two hydrolysates with similar average molecular weight can differ in peptide sequence and functional behavior.
== Medical uses == Atenolol is used for a number of conditions including hyperthyroidism, hypertension, angina, long QT syndrome, acute myocardial infarction, supraventricular tachycardia, ventricular tachycardia, essential tremor (ET), and the symptoms of alcohol withdrawal. The role for β-blockers in general in hypertension was downgraded in June 2006 in the United Kingdom, and later in the United States, as they are less appropriate than other agents such as ACE inhibitors, calcium channel blockers, thiazide diuretics and angiotensin receptor blockers, particularly in the elderly. Atenolol has been used to treat anxiety disorders, such as generalized anxiety disorder and social anxiety disorder. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations, and this may interfere with a positive feedback loop to indirectly reduce psychological anxiety. A 2025 systematic review and meta-analysis that included atenolol found widespread prescription of beta blockers for treatment anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited.
== Research == (2R,6R)-HNK is under development by the National Institute of Mental Health (NIMH) in the United States for the treatment of depression. As of late 2019, it is in phase I clinical trials for this indication. It is also under development under the developmental code name SPL-801-B by Cybin for depressive disorders.
Congenital abnormalities: Atrial septal defect Aortopulmonary window Ebstein's Anomaly Patent Ductus Arteriosus (PDA) Surgical intervention: Transcatheter closure of a PDA Incidence: due to the close proximity of the LRLN to the aortic arch, transient paralysis can occur in 10% of cases while permanent effects can occur in 1% of cases. This can further be attributed to using metal clips (used to control bleeding) during the surgical procedure and is more common in premature infants. Cardiac disease: Left atrial enlargement due to valvular heart disease Notable case: A middle-aged male had ongoing cough, hoarseness of voice, and shortness of breath for two years without a history of smoking was found to have mitral valve stenosis due to calcification. This led to left atrial enlargement, elevated pulmonary artery pressure, pulmonary artery hypertension, and right ventricular enlargement. This cardiomegaly, or enlargement of the heart, led to compression of the LRLN. Atrial Myxoma Aorta: Traumatic injury Incidence: Although injury to the thoracic aorta is often fatal, in 10% of cases that take longer to present, hoarseness may be the first symptom. Aortic dissection More commonly affects the right recurrent laryngeal nerve as the most common type of aortic dissection is type A (Figure 2). Pseudoaneurysm Notable case: A male with long-standing uncontrolled hypertension and hoarseness of voice attributed to life-long smoking was found to have a pseudoaneurysm of the aortic arch which was compressing the LRLN.
==== Variable phenomena – dependently arisen processes ==== The principle of conditionality, which is real and stable, is contrasted with the "dependently arisen processes", which are described as "impermanent, conditioned, dependently arisen, of a nature to be destroyed, of a nature to vanish, of a nature to fade away, of a nature to cease." SA 296 describes them simply as "arising thus according to causal condition, these are called dharmas arisen by causal condition."
Sources: en.wikipedia.org
== History == Lurasidone was first synthesised circa 2003. Lurasidone is a structural analogue of ziprasidone. Lurasidone shows a very close pharmacological profile and has been synthesized similarly to ziprasidone. Lurasidone is chemically similar to perospirone (also a chemical analogue of ziprasidone), as well as risperidone, paliperidone and iloperidone. Lurasidone was developed by Sunovion Pharmaceuticals, a division of Dainippon Sumitomo Pharma Co. of Japan. In 2009, Sunovion decided to develop lurasidone for the treatment of bipolar depression.
South Africa's leading opposition party, the Democratic Alliance, launched a court application to ensure the South African government detained Vladimir Putin and hand him over to the International Criminal Court for war crimes in Ukraine should he "set foot in South Africa." The move followed speculation on whether he would attend the BRICS summit to be held in the country in August, to which the government had granted prior diplomatic immunity to all attendees.
== History == Heparin was discovered by Jay McLean and William Henry Howell in 1916, although it did not enter clinical trials until 1935. It was originally isolated from dog liver cells, hence its name (ἧπαρ hēpar is Greek for 'liver'; hepar + -in). McLean was a second-year medical student at Johns Hopkins University, and was working under the guidance of Howell investigating pro-coagulant preparations when he isolated a fat-soluble phosphatide anticoagulant in canine liver tissue. In 1918, Howell coined the term 'heparin' for this type of fat-soluble anticoagulant. In the early 1920s, Howell isolated a water-soluble polysaccharide anticoagulant, which he also termed 'heparin', although it was different from the previously discovered phosphatide preparations. McLean's work as a surgeon probably changed the focus of the Howell group to look for anticoagulants, which eventually led to the polysaccharide discovery. It had at first been accepted that it was Howell who discovered heparin. However, in the 1940s, Jay McLean became unhappy that he had not received appropriate recognition for what he saw as his discovery. Though relatively discreet about his claim and not wanting to upset his former chief, he gave lectures and wrote letters claiming that the discovery was his. This gradually became accepted as fact, and indeed after he died in 1959, his obituary credited him as being the true discoverer of heparin.
Aside from individual reported experiences, there has been a limited amount of published work summarizing salvia divinorum's effects. A survey of salvia users found that 38% described the effects as unique in comparison to other methods of altering consciousness. 23% said the effects were like yoga, meditation, or trance. Users have written prose about their experiences; some describing their visions pictorially, and there exist examples of 'salvia-inspired' visionary art. Others claim musical inspiration from the plant.
== Regulation == In Europe, regulation is currently split into three areas of regulation: medical devices, medicinal products, and biologics. Tissue engineering products are often of hybrid nature, as they are often composed of cells and a supporting structure. While some products can be approved as medicinal products, others need to gain approval as medical devices. Derksen explains in her thesis that tissue engineering researchers are sometimes confronted with regulation that does not fit the characteristics of tissue engineering. New regulatory regimes have been observed in Europe that tackle these issues. An explanation for the difficulties in finding regulatory consensus in this matter is given by a survey conducted in the UK. The authors attribute these problems to the close relatedness and overlap with other technologies such as xenotransplantation. It can therefore not be handled separately by regulatory bodies. Regulation is further complicated by the ethical controversies associated with this and related fields of research (e.g. stem cells controversy, ethics of organ transplantation). The same survey as mentioned above shows on the example of autologous cartilage transplantation that a specific technology can be regarded as 'pure' or 'polluted' by the same social actor. Two regulatory movements are most relevant to tissue engineering in the European Union.
Sources: en.wikipedia.org
Hydrolysis extent indicates the share of peptide bonds that have been cleaved. It is often estimated from free amino groups and is reported as a percentage. A higher value means smaller peptides and more free amino acids, but it does not by itself define product quality.
No. Whey protein isolate is a filtered protein ingredient with most lactose and fat removed. Hydrolysate refers to protein that has been treated to break peptide bonds, and it can be made from isolate, concentrate, or whey itself.
Not directly. Lactose content depends mainly on the starting material and filtration steps. A hydrolysate made from isolate is typically lower in lactose than one made from sweet whey.
It is whey protein that has been broken into smaller peptides and amino acids through enzymatic or acid hydrolysis. The resulting ingredient is used in food and nutritional products for its altered functional and sensory properties. It is not a single uniform substance because production conditions vary.